All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Aristocrats 2022
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Latest Guru Picks
Real Time Picks
Guru Portfolio
Top 10 Holdings View
Guru Bargains
Hot Picks
Aggregated Portfolio
Consensus Picks
ETFS
Score Board
Sector Picks
International Picks
Industry Trends
Geographic Trend
Options
European Shorting
Economic Data
Industry Overview
U.S. Treasury Yield Curve
Buffett Indicator
Global Market Valuations
Shiller P/E
Shiller P/E by Sectors
GF Value for SP500 Index
Buffett Assets Allocation
Tools
Support
Sean Salmon
The estimated net worth of Sean Salmon is at least $2 Million dollars as of 09/27/2022. Sean Salmon is the EVP & Pres Diabetes/Cardiovasc of Medtronic PLC. Sean Salmon owns over 33,329 shares of Medtronic PLC stock worth over $2 Million .
Sean Salmon
mailing address: MEDTRONIC PLC, 710 MEDTRONIC PARKWAY LC300 MINNEAPOLIS MN 55432
Insider Roles
| Name | Transaction Date | Position |
|---|---|---|
| Medtronic PLC | 2019-11-01 | officer: EVP & Group President Diabetes |
To
Download
Embed
Sean Salmon trading transactions
| Ticker | Company | Current Price | Insider Name | Insider Position | Date | Buy/Sell | Insider Trading Shares | Shares Change | Price | Cost | Final Share | Price Change Since Insider Trade (%) | Filing Date | Dividend Yield % | PE Ratio | Market Cap ($M) |
Select a Column Field to add to the results
Selected (drag to sort)
My Column Fields
No Data
Column Fields
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company | Current Price | Insider Name | Insider Position | Date | Buy/Sell | Insider Trading Shares | Shares Change | Price | Cost | Final Share | Price Change Since Insider Trade (%) | Filing Date | Dividend Yield % | PE Ratio | Market Cap ($M) |
Select a Column Field to add to the results
Selected (drag to sort)
My Column Fields
No Data
Column Fields
| |
MDT | Medtronic PLC | $80.89 | Sean Salmon | EVP & Pres Diabetes/Cardiovasc | 2021-08-25 | Sell | 28,419.00 | -46.02% | $134.08 | $3,810,420.00 | 33,329.00 | -39.67% | - | 3.21 | 21.04 | 107,515.21 |
Add to your portfolio
Total 1
- 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.
Sean Salmon personal network
| Name | Position | Linked company |
|---|
Research Tools
Education
Company
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.
© 2004-2022 GuruFocus.com, LLC. All Rights Reserved.